What INCYTE CORP's SEC filings said

10-Q for 2026Q3, filed 29 Oct 2026, and 1 8-K since. Each line is something a filing stated, ranked by score and linked to its source.

Ranked highest

Research and Development Expense85 · importance in its document · 10-Q · 2026Q3
Research and development expense increased to $1.792 billion in the third quarter of 2026 from $506.6 million a year earlier, and to $2.825 billion for the first nine months from $1.439 billion. The increases include $1.2315 billion of…
Novartis Royalty Litigation Settlement84 · importance in its document · 10-Q · 2026Q3
In May 2025, Incyte and Novartis settled litigation concerning the duration of royalties owed under their Collaboration and License Agreement. Incyte paid Novartis $280.0 million to settle disputed royalties on U.S. JAKAFI net sales…
Operating Income and Margins77 · importance in its document · 8-K exhibit · 29 Oct 2026
Third-quarter 2026 GAAP operating results shifted to a loss of $708.4 million from income of $443.5 million a year earlier; non-GAAP operating loss was $629.7 million versus income of $498.3 million. The reported decline was driven…
Liquidity and Cash Position63 · importance in its document · 10-Q · 2026Q3
At September 30, 2026, Incyte held $3.9 billion in cash, cash equivalents and marketable securities. Operating cash flow for the first nine months fell to $201.7 million from $870.2 million in 2025, primarily because of cash consideration…
Guidance raised60 · rule score among filings · 8-K Item 2.02 · 29 Oct 2026
FOR IMMEDIATE RELEASE Incyte Reports Third Quarter 2026 Financial Results and Provides Business Updates Total revenue of $1.56 billion and total net sales of $1.32 billion in the third quarter of 2026, each an increase of 14% compared to…

Ranked by score, 0–100. A topic read from a document carries its importance within that document; an 8-K event carries the rule score that ranks a filing among filings. Neither is about the share price, and the two scales are named on each row because they are not the same measure.

Latest report: 10-Q · 2026Q3 filed 29 Oct 2026

Full report · Filing on EDGAR

Research and Development ExpenseImportance 85
Research and development expense increased to $1.792 billion in the third quarter of 2026 from $506.6 million a year earlier, and to $2.825 billion for the first nine months from $1.439 billion. The increases include…
Novartis Royalty Litigation SettlementImportance 84 · +1 more on this subject
In May 2025, Incyte and Novartis settled litigation concerning the duration of royalties owed under their Collaboration and License Agreement. Incyte paid Novartis $280.0 million to settle disputed royalties on U.S.…
Liquidity and Cash PositionImportance 63
At September 30, 2026, Incyte held $3.9 billion in cash, cash equivalents and marketable securities. Operating cash flow for the first nine months fell to $201.7 million from $870.2 million in 2025, primarily because…
Revenue Performance and MixImportance 59
Total revenue increased 14.0% to $1.557 billion in the third quarter of 2026 and 23.9% to $4.504 billion in the first nine months, compared with the same periods in 2025. Nine-month net sales rose 24.8% to $3.909…
JAKAFI Demand and PricingImportance 54
JAKAFI net sales increased to $826.5 million in the third quarter of 2026 from $791.1 million a year earlier. Paid demand grew 12% for the quarter and 9% for the first nine months, reflecting continued growth across…
ATEBRIOZ Mirum Licensing DealImportance 43
In April 2026, Incyte granted Mirum worldwide rights to ATEBRIOZ (zilurgisertib), receiving an upfront payment and eligibility for development and regulatory milestones, sales milestones and tiered royalties in the…
Cost of Sales TrendsImportance 41
Cost of sales increased 9.8% to $108.7 million in the third quarter of 2026 and 26.8% to $318.2 million for the first nine months, compared with 2025. Nine-month royalty expense rose to $111.2 million from $90.4…
U.S. Tax Law ChangesImportance 40
The One Big Beautiful Bill Act was enacted in July 2025 and modified key provisions of the 2017 Tax Cuts and Jobs Act. The change permitting expensing of domestic research costs materially reduced Incyte’s U.S. tax…
JAKAFI XR Product LaunchImportance 35
In May 2026, the FDA approved JAKAFI XR, an extended-release ruxolitinib tablet. It is indicated for adults with intermediate- or high-risk myelofibrosis and adults with polycythemia vera who have had an inadequate…
OPZELURA Product ExpansionImportance 35 · +1 more on this subject
OPZELURA (ruxolitinib) cream gained European Commission approval in July 2026 for moderate atopic dermatitis in adults for whom topical corticosteroids and topical calcineurin inhibitors are inadequate or…
OPZELURA Demand and MarketsImportance 33 · +1 more on this subject
Excluding the one-time $246.0 million CMS-related sales benefit, OPZELURA’s nine-month net sales increase was driven by $141.6 million of higher volume, partly offset by an $11.2 million price decrease. U.S. patient…
Income Tax Rate ChangesImportance 32
Incyte recorded income tax provisions of $96.0 million for the third quarter and $302.1 million for the first nine months of 2026, compared with $58.1 million and $287.1 million in 2025. The 2026 effective tax rates…

8-K filings last 12 months

Guidance raised29 Oct 2026 · 8-K Item 2.02 · Flagged · rule score 60
“FOR IMMEDIATE RELEASE Incyte Reports Third Quarter 2026 Financial Results and Provides Business Updates Total revenue of $1.56 billion and total net sales of $1.32 billion in the third quarter of 2026, each an increase of 14% compared to…”
Read from the attached exhibit: Research and Development Expense · Operating Income and Margins · Acquisition / Partnership / Divestiture
Results (release not read)28 Jul 2026 · 8-K Item 2.02 · Routine · rule score 20
Results (release not read)28 Apr 2026 · 8-K Item 2.02 · Routine · rule score 20
Management change (filing not read)30 Mar 2026 · 8-K Item 5.02 · Routine · rule score 20
Executive pay change26 Mar 2026 · 8-K Item 5.02 · Routine · rule score 5
“On March 25, 2026, Incyte Corporation (the “Company”) announced title changes for certain current members of its executive leadership team, effective immediately.”
Results (release not read)10 Feb 2026 · 8-K Item 2.02 · Routine · rule score 20
Management change (filing not read)12 Dec 2025 · 8-K Item 5.02 · Routine · rule score 20

Topics are read from the text of the 10-K, 10-Q or the exhibit attached to an 8-K, each linked to the passage it came from. 8-K events are labelled by fixed rules from the item codes and the filing text — the same rules for every company and every year. The Full Picture merges these with earnings calls and news.